Abstract
Coronavirus disease 2019 (COVID-19) creates a challenge on donor selection, posttransplant management, and immunosuppressive therapy. A question arises about continuing heart transplantation due to risk of immunosuppressive therapy, as well as exposure during hospitalization. After the identification of the first COVID-19 patient, our center conducted the management of selection and treatment of candidates and continued to perform cardiac transplantations. Herein, we present two cases who underwent successful heart transplantation after the determination of patient zero in Türkiye to highlight clinical implications by describing our clinical principle in the ethical knowledge of the International Society for Heart and Lung Transplantation COVID-19 task force statement regarding heart transplantation.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
